PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyDung T. Le, Luis A. Díaz, Atif Zaheer et al.|New England Journal of Medicine|2015Cited by 9.4k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T. Le, Luis A. Díaz, Jennifer N. Durham et al.|Science|2017Cited by 6.6k
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)Dung T. Le, Elizabeth M. Jaffee, Vincent J. Picozzi et al.|Clinical Cancer Research|2019Cited by 260
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic CancerTakahiro Tsujikawa, Dung T. Le, Todd S. Crocenzi et al.|Clinical Cancer Research|2020Cited by 151
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinomaTodd S. Crocenzi, Marka R. Crittenden|Journal for ImmunoTherapy of Cancer|2016Cited by 107